Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Fampridine in KIT Mutant GIST
NCT07171203Phase 1Recruiting
- Sponsor
- University of California, San Diego
- Start
- May 2026
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalfampridine in gastrointestinal stromal tumor (GIST), sponsored by University of California, San Diego. Primary endpoint: Recommended phase 2 dose at 28 days. Started May 2026; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT07171203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171203.